Department of Neurology, Second Hospital of Hebei Medical University, Hebei Medical University Shijiazhuang, Hebei 050000, People's Republic of China.
Hebei Collaborative Innovation Center for Cardio- Cerebrovascular Disease, Shijiazhuang, Hebei 050000, People's Republic of China; Hebei Key Laboratory of Vascular Homeostasis, Shijiazhuang, Hebei 050000, People's Republic of China.
Life Sci. 2022 Jul 1;300:120568. doi: 10.1016/j.lfs.2022.120568. Epub 2022 Apr 27.
In this study, we aimed investigate the impacts of CH-I on angiogenesis, effects for vascular structure changes and long-term neurological recovery after ischemic stroke as well as the potential mechanisms.
Young male mice subjected to intraluminal middle cerebral artery occlusion were administrated with CH-I once daily from day 1 to day 14 after stroke. The infarct volume was evaluated by TTC staining at day 7 after stroke. Neurological deficits were measured 1 to 28 days after stroke. Microvascular density, astrocyte coverage, and angiogenesis were assessed by IF, qRT-PCR, and WB at regular intervals after stroke. LSCI and TPMI measured changes in blood flow and vascular density and width from the day after stroke to day 28.
Compared with the dMCAO group, CH-I treatment significantly improved neurological recovery and reduced the infarct at day 7 after stroke. CH-I treatment increased the expression of the CD31, BrdU/CD31 microvessels and GFAP positive vessels in the peri-infarct cortex at day 7 to 28 after stroke. The expression of protein and gene were enhanced in CH-I group. CH-I significantly improved cerebral blood flow at day 7 after stroke. CH-I increased the vascular density and vascular width at day 14 after stroke.
CH-I has been shown to restore nerve function, reduce the rate of cerebral infarction, increase microvascular density, and promote angiogenesis. CH-I improved cerebral blood flow, protected blood vessels from postoperative stenosis, and improved vascular plasticity.
本研究旨在探讨 CH-I 对血管生成的影响,以及对缺血性脑卒中后血管结构变化和长期神经功能恢复的作用,并探讨其潜在机制。
将雄性年轻小鼠进行大脑中动脉内阻塞(MCAO)后,从卒中后第 1 天至第 14 天每天给予 CH-I 治疗。在卒中后第 7 天通过 TTC 染色评估梗死体积。在卒中后第 1 至 28 天测量神经功能缺损情况。在卒中后定期通过 IF、qRT-PCR 和 WB 评估微血管密度、星形胶质细胞覆盖度和血管生成情况。LSCI 和 TPMI 从卒中后第 1 天至第 28 天测量血流和血管密度及宽度的变化。
与 dMCAO 组相比,CH-I 治疗显著改善了卒中后第 7 天的神经功能恢复,减少了梗死体积。CH-I 治疗增加了卒中后第 7 至 28 天梗死周边皮质中 CD31、BrdU/CD31 微血管和 GFAP 阳性血管的表达。CH-I 组蛋白和基因表达增强。CH-I 显著改善了卒中后第 7 天的脑血流。CH-I 增加了卒中后第 14 天的血管密度和血管宽度。
CH-I 已被证明可恢复神经功能,降低脑梗死发生率,增加微血管密度,促进血管生成。CH-I 改善了脑血流,保护了血管免受术后狭窄,并改善了血管可塑性。